PFE - AstraZeneca CEO Highlights Decade-Long Sales Goal Of $45B Along With Investor Doubts As It Lags In Weight Loss Race | Benzinga
AstraZeneca Plc’s (NASDAQ:AZN) Chief Executive Pascal Soriot says the company achieved a significant milestone by reaching a sales target of $45 billion by 2023, a goal set a decade ago amid pressure from U.S. rival Pfizer Inc (NYSE:PFE).
In November 2013, AstraZeneca received an initial contact on Pfizer’s behalf, proposing that the two companies discuss a combination. AstraZeneca said it was not appropriate to engage in discussions with Pfizer.
Initially facing challenges with revenues at $26 billion and patent expiries, Soriot celebrated the achievement amidst skepticism.
However, despite hitting this milestone, Soriot faces the challenge of convincing investors that AstraZeneca’s best days are not ...